Chemically modified mRNA beyond COVID-19: Potential preventive and therapeutic applications for targeting chronic diseases

被引：13
作者：
Elkhalifa, Dana [1 ]
Rayan, Menatallah [2 ]
Negmeldin, Ahmed T. [3 ,4 ,5 ]
Elhissi, Abdelbary [2 ,6 ,7 ]
Khalil, Ashraf [2 ,6 ]
机构：
[1] Aspetar Orthoped & Sports Med Hosp, Dept Pharm, Doha, Qatar
[2] Qatar Univ, Coll Pharm, Dept Pharmaceut Sci, QU Hlth, Doha, Qatar
[3] Gulf Med Univ, Coll Pharm, Dept Pharmaceut Sci, Ajman, U Arab Emirates
[4] Gulf Med Univ, Thumbay Res Inst Precis Med, Ajman, U Arab Emirates
[5] Cairo Univ, Fac Pharm, Dept Pharmaceut Organ Chem, Cairo, Egypt
[6] Qatar Univ, QU Hlth, Biomed & Pharmaceut Res Unil, Doha, Qatar
[7] Qatar Univ, Off Vice President Res & Grad Studies, Doha, Qatar
来源：
BIOMEDICINE & PHARMACOTHERAPY | 2022年 / 145卷
关键词：
Chemically Modified mRNA; COVID-19; Vaccination; Chronic diseases; Cancer; Diabetes; IN-VITRO; CELLS; DELIVERY; IMMUNOGENICITY; BIOMATERIALS; VACCINATION; FIBROSIS; VACCINES; COLLAGEN; SYSTEM;
D O I：
10.1016/j.biopha.2021.112385
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Chemically modified mRNA represents a unique, efficient, and straightforward approach to produce a class of biopharmaceutical agents. It has been already approved as a vaccination-based method for targeting SARS-CoV-2 virus. The COVID-19 pandemic has highlighted the prospect of synthetic modified mRNA to efficiently and safely combat various diseases. Recently, various optimization advances have been adopted to overcome the limitations associated with conventional gene therapeutics leading to wide-ranging applications in different disease conditions. This review sheds light on emerging directions of chemically modified mRNAs to prevent and treat widespread chronic diseases, including metabolic disorders, cancer vaccination and immunotherapy, musculoskeletal disorders, respiratory conditions, cardiovascular diseases, and liver diseases.
引用
收藏
页数：11
相关论文
共 102 条
  • [1] In vitro Study of a Novel Stent Coating Using Modified CD39 Messenger RNA to Potentially Reduce Stent Angioplasty-Associated Complications
    Abraham, Meike-Kristin
    Nolte, Andrea
    Reus, Rebekka
    Behring, Andreas
    Zengerle, Diane
    Avci-Adali, Meltem
    Hohmann, Jan David
    Peter, Karlheinz
    Schlensak, Christian
    Wendel, Hans Peter
    Krajewski, Stefanie
    [J]. PLOS ONE, 2015, 10 (09):
  • [2] Tendinopathy in Sport
    Ackermann, Paul W.
    Renstrom, Per
    [J]. SPORTS HEALTH-A MULTIDISCIPLINARY APPROACH, 2012, 4 (03): : 193 - 201
  • [3] Messenger RNA delivery of a cartilage-anabolic transcription factor as a disease-modifying strategy for osteoarthritis treatment
    Aini, Hailati
    Itaka, Keiji
    Fujisawa, Ayano
    Uchida, Hirokuni
    Uchida, Satoshi
    Fukushima, Shigeto
    Kataoka, Kazunori
    Saito, Taku
    Chung, Ung-il
    Ohba, Shinsuke
    [J]. SCIENTIFIC REPORTS, 2016, 6
  • [4] Methods to Improve Osseointegration of Dental Implants in Low Quality (Type-IV) Bone: An Overview
    Alghamdi, Hamdan S.
    [J]. JOURNAL OF FUNCTIONAL BIOMATERIALS, 2018, 9 (01)
  • [5] Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results
    Amin, Asim
    Dudek, Arkadiusz Z.
    Logan, Theodore F.
    Lance, Raymond S.
    Holzbeierlein, Jeffrey M.
    Knox, Jennifer J.
    Master, Viraj A.
    Pal, Sumanta K.
    Miller, Wilson H., Jr.
    Karsh, Lawrence I.
    Tcherepanova, Irina Y.
    DeBenedette, Mark A.
    Williams, W. Lee
    Plessinger, Douglas C.
    Nicolette, Charles A.
    Figlin, Robert A.
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2015, 3
  • [6] Systemic Messenger RNA Therapy as a Treatment for Methylmalonic Acidemia (vol 21, pg 3548, 2017)
    An, Ding
    Schneller, Jessica L.
    Frassetto, Andrea
    Liang, Shi
    Zhu, Xuling
    Park, Ji-Sun
    Theisen, Matt
    Hong, Sue-Jean
    Zhou, Jenny
    Rajendran, Raj
    Levy, Becca
    Howell, Rebecca
    Besin, Gilles
    Presnyak, Vladimir
    Sabnis, Staci
    Murphy-Benenato, Kerry E.
    Kumarasinghe, E. Sathyajith
    Salerno, Timothy
    Mihai, Cosmin
    Lukacs, Christine M.
    Chandler, Randy J.
    Guey, Lin T.
    Venditti, Charles P.
    Martini, Paolo G. V.
    [J]. CELL REPORTS, 2018, 24 (09): : 2520 - 2520
  • [7] [Anonymous], Moderna Announces Interim Phase 3 Safety and Immunogenicity Results for mRNA-1010, a Seasonal Influenza Vaccine Candidate
  • [8] Synthetic mRNA Encoding VEGF-A in Patients Undergoing Coronary Artery Bypass Grafting: Design of a Phase 2a Clinical Trial
    Anttila, Vesa
    Saraste, Antti
    Knuuti, Juhani
    Jaakkola, Pekka
    Hedman, Marja
    Svedlund, Sara
    Lagerstrom-Fermer, Maria
    Kjaer, Magnus
    Jeppsson, Anders
    Gan, Li-Ming
    [J]. MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT, 2020, 18 : 464 - 472
  • [9] In Vitro Synthesis of Modified mRNA for Induction of Protein Expression in Human Cells
    Avci-Adali, Meltem
    Behring, Andreas
    Steinle, Heidrun
    Keller, Timea
    Krajeweski, Stefanie
    Schlensak, Christian
    Wendel, Hans P.
    [J]. JOVE-JOURNAL OF VISUALIZED EXPERIMENTS, 2014, (93):
  • [10] Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
    Baden, Lindsey R.
    El Sahly, Hana M.
    Essink, Brandon
    Kotloff, Karen
    Frey, Sharon
    Novak, Rick
    Diemert, David
    Spector, Stephen A.
    Rouphael, Nadine
    Creech, C. Buddy
    McGettigan, John
    Khetan, Shishir
    Segall, Nathan
    Solis, Joel
    Brosz, Adam
    Fierro, Carlos
    Schwartz, Howard
    Neuzil, Kathleen
    Corey, Larry
    Gilbert, Peter
    Janes, Holly
    Follmann, Dean
    Marovich, Mary
    Mascola, John
    Polakowski, Laura
    Ledgerwood, Julie
    Graham, Barney S.
    Bennett, Hamilton
    Pajon, Rolando
    Knightly, Conor
    Leav, Brett
    Deng, Weiping
    Zhou, Honghong
    Han, Shu
    Ivarsson, Melanie
    Miller, Jacqueline
    Zaks, Tal
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (05) : 403 - 416
12345678910